Serum biomarkers of Hepatitis B Virus infected liver and methods for detection thereof

• US 7,257,365 B2
• Filed: 04/26/2004
• Issued: 08/14/2007
• Est. Priority Date: 04/25/2003
• Status: Active Grant

• Current Assignee: University of Hong Kong (Government of Hong Kong Special Administrative Region)
• Original Assignee: University of Hong Kong (Government of Hong Kong Special Administrative Region)
• Inventors: Lau, George, Zhou, Yuan, He, Qing-Yu, Chiu, Jen-Fu
• Primary Examiner(s): Campell; Bruce R.
• Assistant Examiner(s): Peng; Bo
• Application Number:
  US10/831,939
• Publication Number:
  US 20040214164A1
• Time in Patent Office: 1,205 Days
• Field of Search: None
• US Class Current: 434/5
• CPC Class Codes: G01N 2333/775 Apolipopeptides
• CPC Class Codes: G01N 2333/8125 Alpha-1-antitrypsin
• CPC Class Codes: G01N 2333/99 Isomerases (5.)
• CPC Class Codes: G01N 2800/085 Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
• CPC Class Codes: G01N 33/5761 Hepatitis B

Abstract

The invention provides a method for detecting the presence of altered serum proteins in an Hepatitis B Virus (HBV)-infected patient with liver inflammation, comprising: obtaining a sample of serum from the patient; subjecting the sample to protein gel electrophoresis to separate proteins contained therein; staining proteins separated on the electrophoresis gel with silver nitrate solution; scanning the images of stained proteins into an image analysis scanner to obtain gel images; comparing the gel images to control samples of electrophoresis gels prepared from serum of normal patient and serum of HBV-infected patient with liver inflammation to determine whether the sample of serum from the patient contains specific serum proteins. This invention also provides serum protein biomarkers for the diagnosis of patients with HBV infection and liver inflammation.

Claims

1. A method for detecting the presence of Hepatitis B Virus (HBV) infection in a patient being tested for HBV infection, comprising:

obtaining a serum sample from the patient;

subjecting the sample to 2D protein gel electrophoresis to separate proteins contained therein on a 2D electrophoresis gel;

staining proteins separated on the electrophoresis gel;

scanning the image of stained proteins into an image analysis scanner to obtain an image of serum protein expression profile; and

comparing the serum protein expression profile consisting of apolipoprotein A-I (apoA-I), apolipoprotein A-I fragments, haptoglobin β

chain, haptoglobin cleaved β

-chain, haptoglobin 2 chain, apolipoprotein A-IV (apoA-IV), transthyretin, α

1-anitrypsin, α

1-antitrypsin fragments/isoforms, and DNA topoisomerases II (topo-II) obtained from said patient to the protein expression profile obtained from HBV-negative and HBV-infected patients, wherein an altered said protein expression profile compared to HBV-negative patient profiles indicates the presence of HBV infection in the patient.